THE NATURAL-HISTORY OF GASTRIC-CANCER AND PROGNOSTIC FACTORS INFLUENCING SURVIVAL

被引:29
作者
BEDIKIAN, AY
CHEN, TT
KHANKHANIAN, N
HEILBRUN, LK
MCBRIDE, CM
MCMURTREY, MJ
BODEY, GP
机构
[1] UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, CTR CANC, DEPT DEV THERAPEUT, HOUSTON, TX 77030 USA
[2] UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, CTR CANC, DEPT PATHOL, HOUSTON, TX 77030 USA
[3] UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, CTR CANC, DEPT BIOMATH, HOUSTON, TX 77030 USA
[4] UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, CTR CANC, DEPT SURG, HOUSTON, TX 77030 USA
关键词
D O I
10.1200/JCO.1984.2.4.305
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A study of 783 patients with histologically confirmed gastric carcinoma confirmed importance of several previously recognized patient- and tumor-related characteristics related to prognosis and identified some new ones. Of the tumor-related factors, the ones that showed the strongest relationship to survival following curative gastric resection were tumor stage, histologic type, breach of lymph node capsule, sinus histiocytosis and gross appearance. Of the tumor- and patient-related factors, the ones that showed the strongest relationship to survival from time of diagnosis of surgically noncurable disease were status of primary, liver metastasis, serum bilirubin level, ascites, extent of tumor burden and weight loss. The effect of treatment with 5-fluorouracil (5-FU) on survival duration was at best only minimal. Only those patients who received 2 or more cycles of 5-FU therapy had survival advantage over the remaining patients. The use of regression analysis has made it possible to make predictions of the prognosis of the patients. These predictions could be used in future studies to determine comparability of prognosis of various groups included in different studies and different arms of a randomized study.
引用
收藏
页码:305 / 310
页数:6
相关论文
共 17 条
[1]  
BLACK MM, 1971, CANCER, V27, P703, DOI 10.1002/1097-0142(197103)27:3<703::AID-CNCR2820270329>3.0.CO
[2]  
2-K
[3]  
BRUCKNER HW, 1980, P AM ASSOC CANC RES, V21, P180
[4]  
CHEVILLOTTE P, 1981, SEM HOP PARIS, V57, P1941
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
DUPONT BJ, 1980, CURR PROBL CANCER, V4, P3
[7]  
GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203
[8]  
HAWLEY P R, 1970, British Journal of Surgery, V57, P877, DOI 10.1002/bjs.1800571202
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]   5-FLUOROURACIL, DOXORUBICIN, AND MITOMYCIN (FAM) COMBINATION CHEMOTHERAPY FOR ADVANCED GASTRIC-CANCER [J].
MACDONALD, JS ;
SCHEIN, PS ;
WOOLLEY, PV ;
SMYTHE, T ;
UENO, W ;
HOTH, D ;
SMITH, F ;
BOIRON, M ;
GISSELBRECHT, C ;
BRUNET, R ;
LAGARDE, C .
ANNALS OF INTERNAL MEDICINE, 1980, 93 (04) :533-536